Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats.
J Neuroimmunol
; 94(1-2): 109-21, 1999 Feb 01.
Article
em En
| MEDLINE
| ID: mdl-10376943
ABSTRACT
Experimental autoimmune neuritis (EAN) is an autoimmune inflammatory demyelinating disease of the peripheral nervous system (PNS), and represents an animal model of the human Guillain-Barré syndrome (GBS). In this study, we report that nasal administration of the neuritogenic peptide 180-199 and of the cryptic peptide 56-71 of the rat neuritogenic P0 protein of peripheral nerve myelin prevents EAN and attenuates ongoing EAN. Both peptides effectively decreased the severity and shortened clinical EAN. Both a prophylactic and a therapeutic approach proved to be beneficial. These effects were associated with T and B cells hyporesponsiveness to the peptide antigens, reflected by downregulated Th1 cell responses (interferon-gamma secretion) and macrophage function, whereas Th2 cell responses (IL-4 secretion) and transforming growth factor-beta mRNA expression were upregulated.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Terapia de Imunossupressão
/
Proteína P0 da Mielina
/
Neurite Autoimune Experimental
Idioma:
En
Ano de publicação:
1999
Tipo de documento:
Article